LONDON and CAMBRIDGE, Mass.—
Beacon Therapeutics Holdings Limited, an ophthalmic gene therapy company that works to save and restore the vision of patients with blinding retinal diseases, has announced it has raised $170 million in Series B funding to advance the development of ophthalmic gene therapies.
Read more...